Table 3.
Multivariable Cox proportional hazards regression predicting overall survival in a cohort of subjects with prostate cancer (CaP) followed on active surveillance (AS) for primary treatment (N = 886).
| Characteristic | HOR1 (95% CI2) | P value |
|---|---|---|
| Age at diagnosis, years | 0.1122 | |
| <60 | Referent | — |
| 60–60.9 | 1.837 (1.016–3.322) | 0.0441 |
| ≥70 | 1.856 (1.026–3.357) | 0.0408 |
| Race | ||
| White | Referent | — |
| Black | 1.106 (0.805–1.519) | 0.5362 |
| Comorbidities | 0.2714 | |
| 0 | Referent | — |
| 1 | 1.235 (0.877–1.738) | 0.2271 |
| 2 | 1.029 (0.700–1.512) | 0.8847 |
| 3 or more | 1.373 (0.952–1.978) | 0.0895 |
| D'Amico et al. risk strata | <0.0001 | |
| Low | Referent | — |
| Intermediate | 1.612 (1.162–2.237) | 0.0042 |
| High | 2.627 (1.927–3.580) | <0.0001 |
| Secondary treatment type | <0.0001 | |
| None (AS only) | Referent | — |
| RP3 | 0.022 (0.011–0.043) | <0.0001 |
| EBRT-Br4 | 0.052 (0.031–0.087) | <0.0001 |
| HT5 | 0.107 (0.069–0.167) | <0.0001 |
| Dx6 to secondary treatment, months | 0.970 (0.965–0.976) | <0.0001 |
1HOR: hazard Odds Ratio.
2CI: confidence Interval.
3RP: radical prostatectomy.
4EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
5HT: hormone therapy.
6Dx: diagnosis of CaP.